section name header

Pronunciation

fed-RA-ti-nib

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Indications

High Alert


Action

  • Inhibits activated Janus-associated kinase 2 and FMS-like tyrosine kinase 3, which inhibits hematopoietic cell proliferation and causes apoptosis.
Therapeutic effects:
  • Reduction in spleen size and symptoms.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Protein Binding: 92%.

Metabolism/Excretion: Mostly metabolized in the liver via the CYP3A4 and CYP2C19 isoenzymes. Primarily excreted in feces (77%, 23% as unchanged drug), with 5% excreted in urine (3% as unchanged drug).

Half-Life: 114 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2–4 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Inrebic